KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Chemed (CHE) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Chemed (CHE) over the last 17 years, with Q3 2025 value amounting to $129.8 million.

  • Chemed's Cash & Equivalents fell 4558.55% to $129.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.8 million, marking a year-over-year decrease of 4558.55%. This contributed to the annual value of $178.4 million for FY2024, which is 3243.24% down from last year.
  • According to the latest figures from Q3 2025, Chemed's Cash & Equivalents is $129.8 million, which was down 4558.55% from $249.9 million recorded in Q2 2025.
  • Over the past 5 years, Chemed's Cash & Equivalents peaked at $313.3 million during Q1 2024, and registered a low of $7.8 million during Q3 2022.
  • For the 5-year period, Chemed's Cash & Equivalents averaged around $138.7 million, with its median value being $159.9 million (2023).
  • In the last 5 years, Chemed's Cash & Equivalents crashed by 9135.88% in 2022 and then soared by 212529.24% in 2023.
  • Quarter analysis of 5 years shows Chemed's Cash & Equivalents stood at $32.9 million in 2021, then skyrocketed by 125.34% to $74.1 million in 2022, then skyrocketed by 256.09% to $264.0 million in 2023, then plummeted by 32.43% to $178.4 million in 2024, then decreased by 27.25% to $129.8 million in 2025.
  • Its Cash & Equivalents stands at $129.8 million for Q3 2025, versus $249.9 million for Q2 2025 and $173.9 million for Q1 2025.